Beactica Therapeutics initiates IND-enabling studies for BEA-17, a first-in-class LSD1-CoREST degrader for glioblastoma

<p>UPPSALA, Sweden, Sept. 22, 2026 /PRNewswire/ -- Beactica Therapeutics AB, a Swedish precision medicine company, today announced the initiation of IND-enabling studies for BEA-17, the Company's wholly owned, first-in-class oral degrader of the epigenetic regulators LSD1 and CoREST, being...</p>